164 related articles for article (PubMed ID: 15952906)
1. Interferon alpha for the treatment of advanced renal cancer.
Ravaud A; Dilhuydy MS
Expert Opin Biol Ther; 2005 Jun; 5(6):749-62. PubMed ID: 15952906
[TBL] [Abstract][Full Text] [Related]
2. Novel investigative approaches for advanced renal cell carcinoma.
Berg WJ; Divgi CR; Nanus DM; Motzer RJ
Semin Oncol; 2000 Apr; 27(2):234-9. PubMed ID: 10768602
[TBL] [Abstract][Full Text] [Related]
3. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma.
Mickisch GH
Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369
[TBL] [Abstract][Full Text] [Related]
4. Metastatic renal carcinoma long-term survivors treated with s.c. interferon-alpha and s.c. interleukin-2.
Atzpodien J; Reitz M
Cancer Biother Radiopharm; 2005 Aug; 20(4):410-6. PubMed ID: 16114989
[TBL] [Abstract][Full Text] [Related]
5. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review.
Porta C; Szczylik C; Escudier B
Crit Rev Oncol Hematol; 2012 Jun; 82(3):323-37. PubMed ID: 21733715
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy in metastatic cancer of the kidney].
Escudier B
Presse Med; 1995 Oct; 24(32):1504-6. PubMed ID: 8545353
[TBL] [Abstract][Full Text] [Related]
7. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil.
Hofmockel G; Langer W; Theiss M; Gruss A; Frohmüller HG
J Urol; 1996 Jul; 156(1):18-21. PubMed ID: 8648791
[TBL] [Abstract][Full Text] [Related]
8. [Immunotherapy of renal cell carcinoma: results from current phase-III-trials].
Doehn C; Jocham D
Aktuelle Urol; 2004 Apr; 35(2):121-9. PubMed ID: 15146376
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic strategies in kidney cancer--when TKIs are not enough.
Biswas S; Eisen T
Nat Rev Clin Oncol; 2009 Aug; 6(8):478-87. PubMed ID: 19546865
[TBL] [Abstract][Full Text] [Related]
10. [Interferon-alpha therapy in hypernephroma].
Sagaster KP
Wien Med Wochenschr; 1993; 143(16-17):443-7. PubMed ID: 8273370
[TBL] [Abstract][Full Text] [Related]
11. Are we really making an advance in the treatment of metastatic renal cell carcinoma?
Kirkali Z
Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098
[No Abstract] [Full Text] [Related]
12. Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma.
Pantuck AJ; Belldegrun AS; Figlin RA
N Engl J Med; 2001 Dec; 345(23):1711-2. PubMed ID: 11759660
[No Abstract] [Full Text] [Related]
13. Renal cell carcinoma: a priority malignancy for development and study of novel therapies.
Motzer RJ
J Clin Oncol; 2003 Apr; 21(7):1193-4. PubMed ID: 12663704
[No Abstract] [Full Text] [Related]
14. Renal cell cancer: is there long-term survival advantage from cytokine treatment?
Oliver RT
Eur J Cancer; 1994; 30A(9):1214-6. PubMed ID: 7999400
[No Abstract] [Full Text] [Related]
15. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
16. Role of chemotherapy with gemcitabine plus 5-fluorouracil and chemoimmunotherapy in metastatic renal cell cancer (mRCC).
Buti S; Brighenti M; Bongiovanni C; Buzio C; Chiesa MD; Alberici F; Passalacqua R
J Immunother; 2007 Oct; 30(7):780-6. PubMed ID: 17893570
[TBL] [Abstract][Full Text] [Related]
17. Combination recombinant interleukin-2, recombinant interferon-alpha, and 5-fluorouracil for treatment of metastatic renal cell carcinoma.
Ueno NT; Zukiwski AA
Am J Clin Oncol; 1995 Aug; 18(4):358-62. PubMed ID: 7625380
[No Abstract] [Full Text] [Related]
18. New treatment modalities--the urologist's view.
Strohmaier WL
Anticancer Res; 1999; 19(2C):1605-9. PubMed ID: 10365155
[TBL] [Abstract][Full Text] [Related]
19. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
